Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease

Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.

Recent articles in left column more or less in alphabetical order classified

Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

If you want to support us you can do so through a donation: See registration OPS

Chemo and effect in lymphoma, the chemotherapy combination of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) provides significantly better results, longer survival time, the chemotherapy combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy for treating localized aggressive lymphoma

March 25, 2005: Source: Medscape

A chemotherapy combination of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) provides significantly better results - longer survival time and longer period of disease-free time - then the chemotherapy combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy - radiation treatment of localized aggressive lymphoma. This shows a major ten-year randomized double-blind study in 647 lymfklierpatiënten with stage I and II less than 61 years at diagnosis. The researchers now argue for further research into the effect of ACVBP regime coupled with MabThera so ziektevijre period and the survival time even longer. Our tip: use some extra food and nutrients to lymphoma, Hodgkin's disease as well as non-Hodgkin's stories seem nav lymfklierkankerpatiënten an excellent addition to the disease as long as possible to control or perhaps not at all to do.

Here almost literally translated the results from the Phase III study:

Disease-free time and overall survival rates were higher in the ACVBP group than in the CHOP plus radiation group. (P <.001 for both). The five-year disease-free time was 82% (95% confidence interval 2,079,702,307, 78% -87%) for the ACVBP group, and 74% (95% CI, 69% -78%) in the CHOP group. For overall survival, the five-year survival was 90% (95% CI, 87% -93%) and 81% (95% CI, 77% -86%), respectively. Multivariate analysis showed that the results were independent of tumor stage and the presence or absence of 'bulky' disease. We think that with 'bulky' meaning that multiple nodes are affected or not, but we will still check with an expert. An article on Medscape from this phase III study.

March 23, 2005 - The chemotherapy regimen more consistent or dose-Intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) is better than cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy for treating localized aggressive lymphoma, According To the results of a randomized trial published in the March 1924 issue of the New England Journal of Medicine.

"Chemo Radiotherapy is standard treatment for localized aggressive lymphoma," write Felix Reyes, MD, from the Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Creteil, and colleagues from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). "In a previous study or two chemotherapy regimens for intermediate or high grade lymphoma, the EstimatedRunTime five-year rate of overall survival among Patients with localized disease who Received the ACVBP regimen was 80%, Which is similar to results in Other Trials That Used chemo radiotherapy. "

In this study, Previously untreated Patients Younger Than 61 Years with localized stage I or II aggressive lymphoma and no adverse Prognostic factors based on the International Prognostic Index (IPI) Were randomized to receive three cycles of CHOP plus Involved-field radiotherapy (n = 329 ) or chemotherapy alone with ACVBP plus sequential consolidation (n = 318). Median follow-up was 7.7 years.

Event-free and overall survival rates in the ACVBP Were Higher Than in the group CHOP plus radiotherapy group (P <.001 for both). The five-year estimates of event-free survival Were 82% (95% confidence interval 2,079,702,307, 78% -87%) for the ACVBP group, and 74% (95% CI, 69% -78%) for the CHOP group. For overall survival, the five-year estimates Were 90% (95% CI, 87% -93%) and 81% (95% CI, 77% -86%), respectively. Multivariate analysis revealed treatment group That Affected event-free and overall survival rates Independently or tumor stage and the presence or absence of bulky disease.

"In patients under 61 years of age, chemotherapy with three cycles followed by sequential consolidation or ACVBP is superior to three cycles of CHOP plus radiotherapy for the treatment or low-risk localized lymphoma," the authors write. "Efforts are now Needed to Further Improve event-free survival among Such patiënten. Given the benefit of the combination of rituximab and chemotherapy, the GELA HAS undergraduate duties: a trial of rituximab plus the ACVBP regimen in young adults with localized low-risk aggressive lymphoma. "

The Programme Hospitalier de Recherche Clinique du Ministère de la Santé and grants from Amgen, Roche, Schering-Plough, maker or prednisone, and Astra-Medica supported this study.

Accompanying In an editorial, James O. Armitage, MD, from the University of Nebraska Medical Center, Omaha, wonders if the addition under or adjuvant radiotherapy or rituximab Would have changed the results. Dr. Armitage notes That approximately 20% of Patients Treated with ACVBP and More Than 25% Of Those Treatedwith CHOP plus radiotherapy Were not cured.

"As the concept of staging continues to evolve, Multiple Factors Other Than the Ann Arbor stage Will Be important in Predicting prognosis and choosing treatment for Patient with aggressive non-Hodgkin's lymphoma," Dr.. Armitage writes. "Physicians who treat lymphomas with patiënten Hope that we want to continue to move away from the 'one-size-fits-all' approach to the management of aggressive lymphomas."

Dr. Armitage HAS Received consulting fees from GlaxoSmithKline, Corixa, and Geneotope and lecture fees from Genentech, maker or rituximab, Corixa, GlaxoSmithKline, and Amgen.

N Engl J Med. 2005, 352:1197-1205,1250-1252